
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. is well-positioned for growth, primarily due to the strong performance of its lead therapy, cabozantinib, which has established itself as a leading treatment for renal cell carcinoma (RCC) and is expanding into neuroendocrine tumors (NETs) following positive data from the CABINET study. Furthermore, the encouraging results associated with zanzalintinib combined with atezolizumab demonstrate a statistically significant improvement in overall survival, enhancing Exelixis's portfolio and future prospects. The company's focus on expanding its treatment indications and improving patient outcomes, supported by strong long-term data and market positions, suggests a robust growth trajectory.
Bears say
Exelixis Inc. faces a significant patent cliff anticipated by 2031, with projections suggesting an 80% decline in revenues by 2032, which sharply exceeds current market expectations of a 68% drop. The company is also grappling with competitive risks, including erosion of market share for its key drug cabozantinib in renal cell carcinoma (RCC) and disappointing potential for its other treatment indications, which could adversely affect future performance. Furthermore, the potential for approval delays and developmental risks associated with the drug zanzalintinib introduce additional uncertainties that compound the outlook for Exelixis's stock.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares